hepatosplenic T-cell lymphoma (Cancer)
Information
- Disease name
- hepatosplenic T-cell lymphoma
- Disease ID
- DOID:0081049
- Description
- "A mature T-cell and NK-cell lymphoma that is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids and that originates from cytotoxic T-cells, usually of gamma/delta T-cell type." [url:https\://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7596851/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02232516 | Active, not recruiting | Phase 2 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | June 11, 2015 | August 2024 |
| NCT03113500 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | May 25, 2017 | December 21, 2024 |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00040846 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | November 2001 | December 2009 |
| NCT00049504 | Completed | Phase 2 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | January 2002 | February 2014 |
| NCT00072514 | Completed | Phase 2 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | August 2003 | November 2013 |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00131937 | Completed | Phase 2 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | October 2005 | August 2012 |
| NCT00458731 | Completed | Phase 1 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | May 2007 | |
| NCT00536601 | Completed | N/A | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | June 29, 2006 | July 9, 2018 |
| NCT00003196 | Completed | N/A | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | September 1997 | April 2002 |
| NCT00731536 | Completed | Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands | October 2008 | April 2010 | |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00901147 | Completed | Phase 2 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | November 2009 | January 2014 |
| NCT00918333 | Completed | Phase 1/Phase 2 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | June 2009 | July 16, 2019 |
| NCT01075321 | Completed | Phase 1/Phase 2 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | January 10, 2011 | February 13, 2020 |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT01254578 | Completed | Phase 1 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | November 24, 2010 | November 9, 2012 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01261247 | Completed | Phase 2 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | January 17, 2011 | December 2, 2019 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01336933 | Completed | Phase 2 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | July 6, 2011 | December 28, 2016 |
| NCT01427881 | Completed | Phase 2 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | September 2011 | July 2015 |
| NCT01466881 | Completed | Phase 2 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | October 2011 | March 2015 |
| NCT01523223 | Completed | Phase 1 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | January 2012 | October 2016 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01567709 | Completed | Phase 1 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | April 16, 2012 | March 29, 2018 |
| NCT01658319 | Completed | Phase 1 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | May 2011 | May 2015 |
| NCT01748721 | Completed | Phase 1 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2013 | May 2015 |
| NCT01804166 | Completed | Phase 4 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | March 21, 2013 | February 28, 2020 |
| NCT01839916 | Completed | Phase 2 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | April 4, 2013 | August 2018 |
| NCT01959477 | Completed | Early Phase 1 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | March 2014 | April 2015 |
| NCT02168140 | Completed | Phase 1 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | September 2014 | September 15, 2022 |
| NCT02561273 | Completed | Phase 1/Phase 2 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | September 28, 2015 | November 1, 2020 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT01129180 | Completed | Phase 1 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | May 2010 | December 2012 |
| NCT01129193 | Completed | Phase 1 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | May 4, 2010 | January 7, 2017 |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT05377827 | Recruiting | Phase 1 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | October 10, 2023 | April 30, 2026 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT05475925 | Recruiting | Phase 1/Phase 2 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | July 13, 2022 | December 2025 |
| NCT01805037 | Terminated | Phase 1/Phase 2 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | March 5, 2013 | December 31, 2018 |
| NCT00101205 | Terminated | Phase 1 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2004 | |
| NCT01408043 | Terminated | N/A | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | October 2011 | May 2016 |
| NCT01419795 | Terminated | Phase 2 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | May 2012 | |
| NCT01116154 | Terminated | Phase 1 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | May 2010 | August 2010 |
| NCT01678443 | Terminated | Phase 1 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | September 1, 1999 | September 27, 2018 |
| NCT01769222 | Terminated | Phase 1 | Ipilimumab and Local Radiation for Selected Solid Tumors | February 2013 | June 2015 |
| NCT03075553 | Terminated | Phase 2 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | May 17, 2017 | May 29, 2019 |
| NCT00933985 | Terminated | Phase 1 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | June 2009 | April 2013 |
| NCT02742727 | Unknown status | Phase 1/Phase 2 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | March 2016 | March 2018 |
| NCT02533700 | Unknown status | Phase 2 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | September 2015 | December 2020 |
| NCT04639843 | Withdrawn | Phase 1 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | November 3, 2022 | November 3, 2022 |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 | |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT02087878 | Withdrawn | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma | March 31, 2014 | September 30, 2019 |
- Disase is a (Disease Ontology)
- DOID:0050743
- Cross Reference ID (Disease Ontology)
- NCI:C8459
- Cross Reference ID (Disease Ontology)
- ORDO:86882
- ICD10 preferred id (Insert disease from ICD10)
- id-SRFSFto-be-added-later-1249019966288-16
- ICD10 class code (Insert disease from ICD10)
- C86.1